Ivana Vranic
Tadworth, ENG KT207NY, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments.
Journal: Inflammatory bowel diseases
Published: December 19, 2025
Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States.
Journal: Arthritis research & therapy
Published: December 01, 2025
Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis.
Journal: Annals of the rheumatic diseases
Published: November 28, 2025
Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical Programs.
Journal: The American journal of gastroenterology
Published: March 07, 2025
Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE.
Journal: Therapeutic advances in musculoskeletal disease
Published: November 27, 2024
Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.
Journal: Advances in rheumatology (London, England)
Published: January 11, 2024
Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.
Journal: Rheumatology and therapy
Published: December 22, 2023
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
Journal: United European gastroenterology journal
Published: December 20, 2023
Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.
Journal: Rheumatology and therapy
Published: December 02, 2023
Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.
Journal: Rheumatology and therapy
Published: March 14, 2023
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Journal: Annals of the rheumatic diseases
Published: September 27, 2022
Last Updated: 09/26/2026